ArticleThe Journal of pharmacology and experimental therapeutics2010
Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury.
Article in The Journal of pharmacology and experimental therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 39 citations in OpenAlex.
- Exercise mimetics: molecular mechanisms, biological and therapeutic effects.Molecular biomedicine · 2026Review
- Retraction Note: MK801 attenuates secondary injury in a mouse experimental compression model of spinal cord trauma.BMC neuroscience · 2025Article
- Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.Neuromolecular medicine · 2021Review
- Activation of PPAR-β/δ Attenuates Brain Injury by Suppressing Inflammation and Apoptosis in a Collagenase-Induced Intracerebral Hemorrhage Mouse Model.Neurochemical research · 2020Article
- The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis.Experimental eye research · 2020Article
- Hippocampal Genetic Knockdown of PPARδ Causes Depression-Like Behaviors and Neurogenesis Suppression.The international journal of neuropsychopharmacology · 2019Article
- Role of Caspase-8 and Fas in Cell Death After Spinal Cord Injury.Frontiers in molecular neuroscience · 2018Review
- Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.Molecular neurobiology · 2016Review
- PPARδ agonist GW0742 ameliorates Aβ1-42-induced hippocampal neurotoxicity in mice.Metabolic brain disease · 2016Article
- Hippocampal PPARδ Overexpression or Activation Represses Stress-Induced Depressive Behaviors and Enhances Neurogenesis.The international journal of neuropsychopharmacology · 2015Article
- Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits.Molecular neurobiology · 2015Article
- Activation of PPARδ: from computer modelling to biological effects.British journal of pharmacology · 2015Review
- Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.Journal of neuroinflammation · 2015Article
- RNA-seq identifies a role for the PPARβ/δ inverse agonist GSK0660 in the regulation of TNFα-induced cytokine signaling in retinal endothelial cells.Molecular vision · 2015Article
- Development of telmisartan in the therapy of spinal cord injury: pre-clinical study in rats.Drug design, development and therapy · 2015Article
- Nuclear receptors in neurodegenerative diseases.Neurobiology of disease · 2014Review
- Decrease of PPARδ in Type-1-Like Diabetic Rat for Higher Mortality after Spinal Cord Injury.PPAR research · 2014Article
- Ginseng is useful to enhance cardiac contractility in animals.BioMed research international · 2014Article
- Merit of ginseng in the treatment of heart failure in type 1-like diabetic rats.BioMed research international · 2014Article
- Review
Corrections and comments
- Retraction · 2026-04-03Concerns/Issues about Data · Concerns/Issues about Image · Duplication of/in Image · Investigation by Journal/Publisher · Investigation by Third Party · Manipulation of Images · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/10120423B9C19BBC09E2DC3A828E3B
- Erratum issued
- Retracted
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Several lines of evidence suggest a biological role for peroxisome proliferator-activated receptor (PPAR)-beta/delta in the pathogenesis many diseases. The aim of the present study was to evaluate the contribution of PPAR-beta/delta in the secondary damage in experimental spinal cord injury (SCI) in mice. To this purpose, we used 4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid (GW0742), a high-affinity PPAR-beta/delta agonist. Spinal cord trauma was induced by the application of vascular clips (force of 24 g) to the dura via a four-level T5 to T8 laminectomy. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, production of inflammatory mediators, tissue damage, and apoptosis. GW0742 treatment (0.3 mg kg(-1) i.p.) 1 and 6 h after the SCI significantly reduced 1) the degree of spinal cord inflammation and tissue injury (histological score), 2) neutrophil infiltration (myeloperoxidase activity), 3) nitrotyrosine formation, 4) proinflammatory cytokines expression, 5) nuclear factor-kappaB activation, 6) inducible nitric-oxide synthase expression, and 6) apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling staining, FasL, Bax, and Bcl-2 expression). Moreover, GW0742 significantly ameliorated the recovery of limb function (evaluated by motor recovery score). To elucidate whether the protective effects of GW0742 are related to activation of the PPAR-beta/delta receptor, we also investigated the effect of PPAR-beta/delta antagonist methyl 3-({[2-(methoxy)-4 phenyl]amino}sulfonyl)-2-thiophenecarboxylate (GSK0660) on the protective effects of GW0742. GSK0660 (1 mg/kg i.p. 30 min before treatment with GW0742) significantly blocked the effect of the PPAR-beta/delta agonist and thus abolished the protective effect. Our results clearly demonstrate that GW0742 treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.